Investigating the effect of using ketamine on severe and treatment-resistant depressio

Phase 2

• Conditions: depression.; Major depressive disorder, recurrent, unspecified; F33.9

• Registration Number: IRCT20230618058520N1
• Lead Sponsor: Vice Chancellor for Research and Technology, Shahrood Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Patients with treatment-resistant major depressive disorder based on DSM IV _ TR criteria
Being in a depressive episode
Failure to respond to antidepressants and shock medications and failure to control symptoms with other methods
Intolerance of oral antidepressants

Exclusion Criteria

More serious psychiatric disorders: bipolar 1 and 2 - cyclothymia - psychosis - obsession - ski and affective
Addiction or withdrawal from drugs
Personality disorder
Physical diseases such as: thyroid disorders, diabetes, hypertension, stroke, brain surgeries, etc.
Response to drug treatment and control of disease symptoms with drugs
Received ECT two months before starting ketamine treatment
Receiving antidepressant medication one month before starting ketamine treatment
Lack of consent to participate in the study
Cardiovascular problems
Pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression score in Beck and Hamilton test. Timepoint: Comparison of Hamilton and Beck test results before injection, two days after injection, one week after injection, one month after injection. Method of measurement: The criterion of response to ketamine treatment is a decrease of 50% or more in Beck and Hamilton tests.